Genter Capital股利收益主動型ETF GEND 深 滬
等待開盤 01-07 09:30:00 美东时间
11.795
+0.060
+0.51%
華盛通- 最 高11.795
- 今 開11.75
- 成交量 2.64万股
- 最 低 11.75
- 昨 收 11.735
- 總市值 70.77万
- 52周最高 11.795
- 市盈率 靜 --
- 換手率 43.93%
- 52周最低 8.9804
- 委 比 88.89%
- 總股本 6.00万
- 歷史最高 11.795
- 量 比 1.35
- 振 幅 0.38%
- 歷史最低 8.9804
- 每 手 1
- 風險率 0.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多enGene Holdings GAAP EPS of $2.29
enGene Holdings press release (ENGN): FY GAAP EPS of $2.29. Full Year Financial Results ended October 31, 2025Total operating expenses were $123.2 million for the full year ended October 31, 2025, com...
2025-12-23 05:05
Here’s Why enGene Holdings Stock Is Soaring Today
enGene Holdings ($ENGN) stock is soaring on Tuesday after releasing promising p...
2025-11-12 03:06
enGene’s Detalimogene Shows Promising Results in Bladder Cancer Trial
enGene Holdings ( ($ENGN) ) has issued an announcement. enGene Holdings Inc. ha...
2025-11-11 21:09
EnGene's Additional Data From Phase 2 LEGEND Study Of Detalimogene Voraplasmid Demonstrates Enhanced Complete Response Rate Of 63% In 62 Participants; Overall Safety Of Detalimogene Favorable
enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today reported additional preliminary data from the pivotal cohort of its ongoing, Phase 2 LEGEND
2025-11-11 20:36
Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 7, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – Major pharmaceutical companies presenting at...
2025-10-07 20:00
ROYAL CARIBBEAN UNVEILS THE NEW LEGEND OF THE SEAS WITH NEXT-LEVEL FAMILY EXPERIENCES
The Icon Class vacation sets the bar with more dining spots, new entertainment and ways to play in July 2026 MIAMI, Oct. 6, 2025 /PRNewswire/ -- Royal Caribbean is introducing the family tim...
2025-10-06 20:26
enGene Holdings Reaches Target Enrollment Of 100 Patients For Pivotal Cohort Of Its Ongoing, Open-Label, Multi-Cohort Phase 2 LEGEND Trial Of Detalimogene Voraplasmid In Patients With High-Risk, NMIBC
Target enrollment of 100 patients with high-risk, BCG-unresponsive NMIBC with CIS achievedenGene plans to provide an update from LEGEND's pivotal cohort in 4Q 2025Biologic License Application (BLA) submission planned for
2025-09-03 19:35
Inspired Entertainment To Sell UK Holiday Parks Business To GENDA For $25.1M In Cash; Inspired To Provide Gaming Content, Platform Services On Recurring Revenue Basis To Indigo NewCo
Inspired Entertainment, Inc. ("Inspired" or the "Company") (NASDAQ:INSE), a leading B2B provider of gaming content, technology, hardware, and services, today announced that it has entered into a definitive agreement with
2025-08-27 19:13
《逆境突破》将亮相2025 ChinaJoy
北京瀚翔科技发展有限公司在Steam平台上即将推出的下一代大逃杀游戏《逆境突破》（LEGEND BATTLES）的开发团队宣布，该游戏将在2025年China...
2025-07-31 10:16
enGene Holdings Announces The U.S. FDA Has Granted Regenerative Medicine Advanced Therapy Designation To Detalimogene Voraplasmid For Expedited Review In High-Risk, Non-Muscle Invasive Bladder Cancer
Regenerative Medicine Advanced Therapy (RMAT) designation provides access to accelerated development toolsDesignation recognizes the potential of detalimogene to address significant unmet needenGene Holdings Inc.
2025-06-25 20:12
